Palisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary

Palisade Bio

10/08/2026 22:40

Palisade Bio Inc PALI.OQ reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -58 cents.  The mean expectation of nine analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -7 cents to -4 cents per share.
Revenue was $500.00 thousand​; analysts expected zero. 
Palisade Bio Inc's reported EPS for the quarter was a loss of 5 cents​.
The company reported a quarterly loss of $10.57 million.
Palisade Bio Inc shares had risen by 1.0% this quarter and lost 10.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 10.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Palisade Bio Inc is $8.00, about 73.6% above its last closing price of $2.11
This summary was machine generated from LSEG data August 10 at 09:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.05
-0.05
Met
Mar. 31 2026 
-0.04
-0.05
Missed
Dec. 31 2025 
-0.08
-0.08
Met
Sep. 30 2025 
-0.27
-0.38
Missed